To further confirm the anticancer effects in vivo, a subcutaneous prostate tumor-bearing mice model was established by subcutaneously injecting 106 TPH1-overexpressing PC-3 cells into immunodeficient mice. Here, TPH1 is linked to prostate neoplasm.